University of North Carolina at Chapel Hill's Gene Therapy Department

Gene Therapy Department - University of North Carolina at Chapel Hill

Samulski Lab
Kafri Lab
Monahan Lab
McCown Lab

Vector Core Facilities

MJFF Request
MTA
Clinical Wing
Research Wing

Clinical Trials

Directors Offices
Employment
Contributions

Strategic Partners

Asklepios
MDA
Duke University
Robert Wood Johnson
Ohio State University
University of Pittsburgh

Gene Therapy Links

Tal Kafri MD, PhD

Associate Professor

MD/PhD Hebrew University, Jerusalem

919.843.7635

kafri@med.unc.edu

Research Interests: The development of lentivirus vectors for gene therapy, and on basic science of

HIV-1 biology.

Publications:

Kantor B, Bayer M, Ma H, Samulski J, Li C, McCown T, Kafri T. Notable Reduction in Illegitimate Integration Mediated by a PPT-deleted, Nonintegrating Lentiviral Vector. Mol Ther. 2011 Mar;19(3):547-56. Epub 2010 Dec 14. PMID: 21157436

Monahan PE, Lothrop CD, Sun J, Hirsch ML, Kafri T, Kantor B, Sarkar R, Tillson DM, Elia JR, Samulski RJ. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther. 2010 Nov;18(11):1907-16. Epub 2010 Aug 10.PMID: 20700109

Yuen EY, Liu W, Kafri T, van Praag H, Yan Z. Regulation of AMPA receptor channels and synaptic plasticity by cofilin phosphatase Slingshot in cortical neurons. J Physiol. 2010 Jul 1;588(Pt 13):2361-71. Epub 2010 May 4.PMID: 20442266

Kantor B, Ma H, Webster-Cyriaque J, Monahan PE, Kafri T. Epigenetic activation of unintegrated HIV-1 genomes by gut-associated short chain fatty acids and its implications for HIV infection. Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18786-91. Epub 2009 Oct 20. PMID: 19843699

Bayer M, Kantor B, Cockrell A, Ma H, Zeithaml B, Li X, McCown T, Kafri T. A Large U3 Deletion Causes Increased In Vivo Expression From a Nonintegrating Lentiviral Vector. Mol Ther. 2008 Sep 16. [Epub ahead of print]

Cockrell AS, Kafri T. Gene delivery by lentivirus vectors. Mol Biotechnol. 2007 Jul; 36 ( 3 ): 184-204 . Review.

Li C, Hirsch M, Asokan A, Zeithaml B, Ma H, Kafri T, Samulski RJ. Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. J Virol. 2007 Jul; 81 ( 14 ): 7540-7 . Epub 2007 May 2.

Bahi A, Boyer F, Kafri T, Dreyer JL. Silencing urokinase in the ventral tegmental area in vivo induces changes in cocaine-induced hyperlocomotion. J Neurochem. 2006 Sep; 98 ( 5 ): 1619-31 .

Cockrell AS, Ma H, Fu K, McCown TJ, Kafri T. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. Mol Ther. 2006 Aug; 14 ( 2 ): 276-84 . Epub 2006 Mar 3.

Bahi A, Boyer F, Gumy C, Kafri T, Dreyer JL. In vivo gene delivery of urokinase-type plasminogen activator with regulatable lentivirus induces behavioural changes in chronic cocaine administration. Eur J Neurosci. 2004 Dec; 20 ( 12 ): 3473-88 .

Haack K, Cockrell AS, Ma H, Israeli D, Ho SN, McCown TJ, Kafri T. Transactivator and structurally optimized inducible lentiviral vectors. Mol Ther. 2004 Sep; 10 ( 3 ): 585-96 .

Logan AC, Haas DL, Kafri T, Kohn DB. Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration. J Virol. 2004 Aug; 78 ( 16 ): 8421-36 .

Ma H, Kafri T. A single-LTR HIV-1 vector optimized for functional genomics applications. Mol Ther. 2004 Jul; 10 ( 1 ): 139-49 .

Bahi A, Boyer F, Kafri T, Dreyer JL. CD81-induced behavioural changes during chronic cocaine administration: in vivo gene delivery with regulatable lentivirus. Eur J Neurosci. 2004 Mar; 19 ( 6 ): 1621-33 .

UNC Gene Therapy Center Contact Information